HK이노엔

195940KOSDAQ의약품 제조업

52.0 / 100

Reference Date: 2026-04-13

Financial Score19.5 / 40

News Sentiment12.5 / 25

Momentum10.0 / 20

Disclosure10.0 / 15

AI Analysis: ROE is above the industry average but ROE is below the industry average. Slightly down 4.3% over the past month, and news sentiment is neutral.

Company InformationBased on 2025 Annual Report

Business Overview

HK Inoent is a pharmaceutical company primarily engaged in ETC (Specialty Pharmaceuticals) and H&B (Health & Beauty) businesses, achieving sales of 1.632 trillion KRW and operating profit of 110.9 billion KRW in 2025 through key products like K-Cap and H&B items such as Condition. Established in 1984, the company expanded through the acquisition of Hanil Pharm in 2006 and Hanacolma in 2018, focusing on R&D and global market expansion.

Number of Employees

1,723people

Average Salary

84.6M KRW

Score Calculation Basis

Detailed Financial Score

PER

18.10Industry Average 14.803.0Point

Higher than industry avg (caution)

PBR

1.03Industry Average 1.044.0Point

In line with industry avg

ROE

5.87Industry Average 4.424.0Point

In line with industry avg

Debt Ratio

13.25Industry Average 11.982.0Point

Higher than industry avg (caution)

Trend 2023~20256.5 / 10 points

Revenue Growth Rate

2.5 / 3

Avg ▲13.4% (2-year basis)

Operating Profit Growth Rate

3.0 / 3

Avg ▲29.8% (2-year basis)

ROE Trend

1.0 / 4

Avg ROE 5.0% (improving, 3yr)

Detailed News Sentiment

11 totalPositive 0Neutral 6Negative 0Average Sentiment Score 50

Detailed Momentum

52-week position5.0Point

52w mid range (55%)

Current 48,350Won52-week high 57,60052-week low 36,800

1-month return2.0Point

1m -4.26% (slight drop)

Volume trend3.0Point

Volume flat

Detailed Disclosure

8 totalPositive 0Neutral 8Negative 0

Neutral임원ㆍ주요주주특정증권등소유상황보고서2026-04-07
Neutral임원ㆍ주요주주특정증권등소유상황보고서2026-04-02
Neutral사외이사의선임ㆍ해임또는중도퇴임에관한신고2026-04-01
Neutral투자판단관련주요경영사항(임상시험계획승인신청) (경증에서 중등증 아토피 피부염 치료 후보물질 IN-115314 임상 1b상 임상시험계획(IND) 미국 식품의약국(FDA) 제출)2026-04-01
Neutral사외이사의선임ㆍ해임또는중도퇴임에관한신고2026-03-26